Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

Int J Med Sci 2024; 21(8):1575-1588. doi:10.7150/ijms.91584 This issue Cite

Review

F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects

Yanzhen Yang1,2, Qu Xie1,2, Can Hu2, Jingli Xu2, Lei Chen2, Yuan Li2✉, Cong Luo2✉

1. Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China.
2. Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310005, China.

✉ Corresponding authors: Cong Luo: luocongorg.cn; Yuan Li: yuanli909909com. 1 Banshandong, Road, Hangzhou, 310005, China.

Citation:
Yang Y, Xie Q, Hu C, Xu J, Chen L, Li Y, Luo C. F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Int J Med Sci 2024; 21(8):1575-1588. doi:10.7150/ijms.91584. https://www.medsci.org/v21p1575.htm
Other styles

File import instruction

Abstract

Graphic abstract

Gastric cancer (GC) is a prevalent malignancy characterized by significant morbidity and mortality, yet its underlying pathogenesis remains elusive. The etiology of GC is multifaceted, involving the activation of oncogenes and the inactivation of antioncogenes. The ubiquitin-proteasome system (UPS), responsible for protein degradation and the regulation of physiological and pathological processes, emerges as a pivotal player in GC development. Specifically, the F-box protein (FBP), an integral component of the SKP1-Cullin1-F-box protein (SCF) E3 ligase complex within the UPS, has garnered attention for its prominent role in carcinogenesis, tumor progression, and drug resistance. Dysregulation of several FBPs has recently been observed in GC, underscoring their significance in disease progression. This comprehensive review aims to elucidate the distinctive characteristics of FBPs involved in GC, encompassing their impact on cell proliferation, apoptosis, invasive metastasis, and chemoresistance. Furthermore, we delve into the emerging role of FBPs as downstream target proteins of non-coding RNAs(ncRNAs) in the regulation of gastric carcinogenesis, outlining the potential utility of FBPs as direct therapeutic targets or advanced therapies for GC.

Keywords: F-box proteins, Gastric cancer, Mechanism, Non-coding RNA, Chemoresistance

Citation styles

APA
Yang, Y., Xie, Q., Hu, C., Xu, J., Chen, L., Li, Y., Luo, C. (2024). F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. International Journal of Medical Sciences, 21(8), 1575-1588. https://doi.org/10.7150/ijms.91584.

ACS
Yang, Y.; Xie, Q.; Hu, C.; Xu, J.; Chen, L.; Li, Y.; Luo, C. F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Int. J. Med. Sci. 2024, 21 (8), 1575-1588. DOI: 10.7150/ijms.91584.

NLM
Yang Y, Xie Q, Hu C, Xu J, Chen L, Li Y, Luo C. F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Int J Med Sci 2024; 21(8):1575-1588. doi:10.7150/ijms.91584. https://www.medsci.org/v21p1575.htm

CSE
Yang Y, Xie Q, Hu C, Xu J, Chen L, Li Y, Luo C. 2024. F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Int J Med Sci. 21(8):1575-1588.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use